Table 3: Clinical outcome during follow-up.
| Patient |
The Period from Onset to Renal Biopsy (months) |
Treatment |
The period from Treatment Initiation to Remission (months) |
Renal Dysfunction |
Follow-up After Treatment Initiation (months) |
| 1 |
3 |
ACE-I |
5 |
- |
66 |
| 2 |
1 |
PSL |
2 |
- |
37 |
| 3 |
NA |
PSL, ACE-I, ARB |
16 |
- |
75 |
| 4 |
2 |
PSL |
19 |
- |
106 |
| 5 |
1 |
PSL |
8 |
- |
138 |
| 6 |
1 |
PSL |
5 |
- |
50 |
| 7 |
2 |
ACE-I |
13 |
- |
40 |
| 8 |
2 |
ACE-I |
9 |
- |
33 |
| 9 |
9 |
ACE-I |
5 |
- |
11 |
| 10 |
7 |
ACE-I |
no remission |
- |
7 |
| 11 |
3 |
ACE-I |
no remission |
- |
11 |
PSL: prednisolone, ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker, NA: data not available